Pharmacophore modelling as a virtual screening tool for the discovery of small molecule protein-protein interaction inhibitors

Current Pharmaceutical Design

Volumn 18, Issue 30, 2012, Pages 4586-4598

  Voet, Arnout ^a   Zhang, Kam Y J ^a  

^a RIKEN   (Japan)

Author keywords

14 3 3; Bcr abl; Drug discovery; HIV; Integrase; LEDGF p75; LEDGINS; Lysozyme; Pharmacophore modeling; PliC; Protein protein interaction; PUMA; Reverse transcriptase; Small molecule inhibitor; SMPPII; Virtual screening

Indexed keywords

ABELSON KINASE; ANTIRETROVIRUS AGENT; CX 04328; DASATINIB; DRUG; INTEGRASE; INTEGRASE INHIBITOR; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; LYSOZYME; NILOTINIB; PROTEIN 14 3 3; PROTEIN BCL 2; PUMA PROTEIN; RALTEGRAVIR; SMALL MOLECULE PROTEIN PROTEIN INTERACTION INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CHRONIC MYELOID LEUKEMIA; CONFORMATION; CRYSTAL STRUCTURE; DIMERIZATION; DRUG SCREENING; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROGEN BOND; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS REPLICATION;

COMPUTER SIMULATION; DRUG DISCOVERY; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; PROTEINS; SMALL MOLECULE LIBRARIES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84866403586     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802651616     Document Type: Review

References (100)

1. Verdine GL, Walensky LD. The challenge of drugging undrug gable targets in cancer: lessons learned from targeting BCL- 2 family members. Clin Cancer Res 2007; 13: 7264-7270.
2. Wells JA, McClendon CL. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007; 450: 1001-1009.
3. Marshall G. Three-dimensional structure of peptide-protein complexes: implications for recognition. Current Opinion in Structural Biology 1992; 2: 904-919
4. Lo Conte L, Chothia C, Janin J. The atomic structure of proteinprotein recognition sites. J Mol Biol 1999; 285: 2177-2198.
5. Yin H, Hamilton AD. Strategies for targeting protein-protein interactions with synthetic agents. Angew Chem Int Ed Engl 2005; 44: 4130-4163.
6. Berg T. Small-molecule inhibitors of protein-protein interactions. Curr Opin Drug Discov Devel 2008; 11: 666-674.
7. Rechfeld F, Gruber P, Hofmann J, Kirchmair J. Modulators of protein-protein interactions: novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. Curr Top Med Chem 2011; 11: 1305-1319.
8. Meireles LM, Mustata G. Discovery of Modulators of Protein- Protein Interactions: Current Approaches and Limitations. Curr Top Med Chem 2010.
9. Pagliaro L, Felding J, Audouze K, et al. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr Opin Chem Biol 2004; 8: 442-449.
10. Wilson AJ. Inhibition of protein-protein interactions using designed molecules. Chem Soc Rev 2009; 38: 3289-3300.
11. Morelli X, Bourgeas R, Roche P. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). Curr Opin Chem Biol 2011; 15: 475-481.
12. Fletcher S, Hamilton AD. Protein-protein interaction inhibitors: small molecules from screening techniques. Curr Top Med Chem 2007; 7: 922-927.
13. Hajduk PJ. SAR by NMR: putting the pieces together. Mol Interv 2006; 6: 266-72.
14. Zhang S. Computer-aided drug discovery and development. Methods Mol Biol 2011; 716: 23-38.
15. Bottegoni G. Protein-ligand docking. Front Biosci; 17: 2289-2306.
16. Caporuscio F, Tafi A. Pharmacophore modelling: a forty year old approach and its modern synergies. Curr Med Chem 2011; 18: 2543-2553.
17. Fry DC. Drug-like inhibitors of protein-protein interactions: a structural examination of effective protein mimicry. Curr Protein Pept Sci 2008; 9: 240-247.
18. Bourgeas R, Basse MJ, Morelli X, Roche P. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PLoS One 2010; 5: e9598.
19. Masood A, Azmi AS, Mohammad RM. Small Molecule Inhibitors of Bcl-2 Family Proteins for Pancreatic Cancer Therapy. Cancers (Basel) 2011; 3: 1527-1549.
20. Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009; 49: 223-241.
21. Tsao DH, Sutherland AG, Jennings LD, et al. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design. Bioorg Med Chem 2006; 14: 7953-7961.
22. Rajapakse HA. Small molecule inhibitors of the XIAP proteinprotein interaction. Curr Top Med Chem 2007; 7: 966-971.
23. Wilson CG, Arkin MR. Small-molecule inhibitors of IL-2/IL-2R: lessons learned and applied. Curr Top Microbiol Immunol 2010; 348: 25-59.
24. He MM, Smith AS, Oslob JD, et al. Small-molecule inhibition of TNF-alpha. Science 2005; 310: 1022-1025.
25. Goudreau N, Cameron DR, Deziel R, et al. Optimization and determination of the absolute configuration of a series of potent inhibitors of human papillomavirus type-11 E1-E2 protein-protein interaction: a combined medicinal chemistry, NMR and computational chemistry approach. Bioorg Med Chem 2007; 15: 2690-2700.
26. Davey DD, Adler M, Arnaiz D, et al. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors. J Med Chem 2007; 50: 1146-157.
27. Ullrich T, Baumann K, Welzenbach K, et al. Statin-derived 1,3- oxazinan-2-ones as submicromolar inhibitors of LFA-1/ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain. Bioorg Med Chem Lett 2004; 14: 2483-2487.
28. Gadek TR, Burdick DJ, McDowell RS, et al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science 2002; 295: 1086-1089.
29. Mustata G, Follis AV, Hammoudeh DI, et al. Discovery of novel Myc-Max heterodimer disruptors with a three-dimensional pharmacophore model. J Med Chem 2009; 52: 1247-12450.
30. Jacoby E, Boettcher A, Mayr LM, et al. Knowledge-based virtual screening: application to the MDM4/p53 protein-protein interaction. Methods Mol Biol 2009; 575: 173-194.
31. Bowman AL, Nikolovska-Coleska Z, Zhong H, Wang S, Carlson HA. Small molecule inhibitors of the MDM2-p53 interaction discovered by ensemble-based receptor models. J Am Chem Soc 2007; 129: 12809-12814.
32. Pinto M, Orzaez Mdel M, Delgado-Soler L, Perez JJ, Rubio- Martinez J. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein. J Chem Inf Model 2011; 51: 1249-1258.
33. Almerico AM, Tutone M, Lauria A. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors. Eur J Med Chem 2010; 45: 4774-4782.
34. Voet AR, Maeyer MD, Debyser Z, Christ F. In search of secondgeneration HIV integrase inhibitors: targeting integration beyond strand transfer. Future Med Chem 2009; 1: 1259-1274.
35. Nguyen BY, Isaacs RD, Teppler H, et al. Raltegravir: the first HIV-1 integrase strand transfer inhibitor in the HIV armamentarium. Ann N Y Acad Sci 2011; 1222: 83-89.
36. Blanco JL, Varghese V, Rhee SY, Gatell JM, Shafer RW. HIV-1 integrase inhibitor resistance and its clinical implications. J Infect Dis 2011; 203: 1204-1214.
37. Cherepanov P, Maertens G, Proost P, et al. HIV-1 integrase forms stable tetramers and associates with LEDGF/p75 protein in human cells. J Biol Chem 2003; 278: 372-381.
38. Cherepanov P, Devroe E, Silver PA, Engelman A. Identification of an evolutionarily conserved domain in human lens epitheliumderived growth factor/transcriptional co-activator p75 (LEDGF/p75) that binds HIV-1 integrase. J Biol Chem 2004; 279: 48883-48892.
39. Llano M, Saenz DT, Meehan A, et al. An essential role for LEDGF/p75 in HIV integration. Science 2006; 314: 461-464.
40. Vandekerckhove L, Christ F, Van Maele B, et al. Transient and stable knockdown of the integrase cofactor LEDGF/p75 reveals its role in the replication cycle of human immunodeficiency virus. J Virol 2006; 80: 1886-1896.
41. Emiliani S, Mousnier A, Busschots K, et al. Integrase mutants efective for interaction with LEDGF/p75 are impaired in chromosome tethering and HIV-1 replication. J Biol Chem 2005; 280: 25517-25523.
42. De Rijck J, Vandekerckhove L, Gijsbers R, et al. Over expression of the lens epithelium-derived growth factor/p75 integrase binding domain inhibits human immunodeficiency virus replication. J Virol 2006; 80: 11498-1509.
43. Cherepanov P, Ambrosio AL, Rahman S, Ellenberger T, Engelman A. Structural basis for the recognition between HIV-1 integrase and transcriptional coactivator p75. Proc Natl Acad Sci U S A 2005; 102: 17308-17313.
44. Du L, Zhao Y, Chen J, et al. D77, one benzoic acid derivative, functions as a novel anti-HIV-1 inhibitor targeting the interaction between integrase and cellular LEDGF/p75. Biochem Biophys Res Commun 2008; 375: 139-144.
45. Li P, Tan JJ, Liu M, Zhang XY, Chen WZ, Wang CX. Insight into the Inhibitory Mechanism and Binding Mode Between D77 and HIV-1 Integrase by Molecular Modeling Methods. J Biomol Struct Dyn 2011; 29: 311-323.
46. De Luca L, Barreca ML, et al. Pharmacophore-based discovery of small-molecule inhibitors of protein-protein interactions between HIV-1 integrase and cellular cofactor LEDGF/p75. ChemMedChem 2009; 4: 1311-136.
47. Wolber G, Langer T. LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model 2005; 45: 160-169.
48. Hou Y, McGuinness DE, Prongay AJ, et al. Screening for antiviral inhibitors of the HIV integrase-LEDGF/p75 interaction using the AlphaScreen luminescent proximity assay. J Biomol Screen 2008; 13: 406-414.
49. Goodford PJ. A computational procedure for determining energetically favorable binding sites on biologically important macromolecules. J Med Chem 1985; 28: 849-875.
50. De Luca L, Ferro S, Gitto R, et al. Small molecules targeting the interaction between HIV-1 integrase and LEDGF/p75 cofactor. Bioorg Med Chem 2010; 18: 7515-7521.
51. Christ F, Voet A, Marchand A, et al. Rational design of smallmolecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nature Chemical Biology 2010; 6: 442-448.
52. Maignan S, Guilloteau JP, Zhou-Liu Q, Clement-Mella C, Mikol V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases. J Mol Biol 1998; 282: 359-368.
53. Molteni V, Greenwald J, Rhodes D, et al. Identification of a smallmolecule binding site at the dimer interface of the HIV integrase catalytic domain. Acta Crystallogr D Biol Crystallogr 2001; 57: 536-544.
54. Pannecouque C, Daelemans D, De Clercq E. Tetrazolium-based colorimetric assay for the detection of HIV replication inhibitors: revisited 20 years later. Nat Protoc 2008; 3: 427-434.
55. K.U. Leuven, Leuven enters into license agreement with Pfizer In: ed.^eds. 2010.
56. Cavalluzzo C, Voet A, Christ F, et al. De novo design of small molecule inhibitors targeting the LEDGF/p75-HIV integrase interaction. RSC Advances 2012; 2: 974.
57. Bartholomeeusen K, De Rijck J, Busschots K, et al. Differential interaction of HIV-1 integrase and JPO2 with the C terminus of LEDGF/p75. J Mol Biol 2007; 372: 407-421.
58. McWhirter JR, Wang JY. An actin-binding function contributes to transformation by the Bcr-Abl oncoprotein of Philadelphia chromosome-positive human leukemias. EMBO J 1993; 12: 1533-1546.
59. Druker BJ. Translation of the Philadelphia chromosome into therapy for CML. Blood 2008; 112: 4808-4817.
60. Weisberg E, Manley PW, Cowan-Jacob SW, Hochhaus A, Griffin JD. Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia. Nat Rev Cancer 2007; 7: 345-356.
61. Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood 2009; 114: 5426-5435.
62. Yoshida K, Yamaguchi T, Natsume T, Kufe D, Miki Y. JNK phosphorylation of 14-3-3 proteins regulates nuclear targeting of c- Abl in the apoptotic response to DNA damage. Nat Cell Biol 2005; 7: 278-285.
63. Mancini M, Veljkovic N, Corradi V, et al. 14-3-3 ligand prevents nuclear import of c-ABL protein in chronic myeloid leukemia. Traffic 2009; 10: 637-647.
64. Wang B, Yang H, Liu YC, Jelinek T, Zhang L, Ruoslahti E, Fu H. Isolation of high-affinity peptide antagonists of 14-3-3 proteins by phage display. Biochemistry 1999; 38: 12499-12504.
65. Wilker EW, Grant RA, Artim SC, Yaffe MB. A structural basis for 14-3-3sigma functional specificity. J Biol Chem 2005; 280: 18891-18898.
66. Cui Y. Using molecular simulations to probe pharmaceutical materials. J Pharm Sci 2011; 100: 2000-2019.
67. Mancini M, Corradi V, Petta S, et al. A new nonpeptidic inhibitor of 14-3-3 induces apoptotic cell death in chronic myeloid leukemia sensitive or resistant to imatinib. J Pharmacol Exp Ther 2010; 336: 596-604.
68. Corradi V, Mancini M, Santucci MA, et al. Computational techniques are valuable tools for the discovery of protein-protein interaction inhibitors: The 14-3-3sigma case. Bioorg Med Chem Lett 2011.
69. Fulda S, Debatin KM. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy. Oncogene 2006; 25: 4798-47811.
70. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
71. Yu J, Zhang L. PUMA, a potent killer with or without p53. Oncogene 2008; 27 Suppl 1: S71-S83.
72. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell 2001; 7: 673-682.
73. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001; 7: 683-694.
74. Wu WS, Heinrichs S, Xu D, et al. Slug antagonizes p53-mediated apoptosis of hematopoietic progenitors by repressing puma. Cell 2005; 123: 641-653.
75. Qiu W, Carson-Walter EB, Liu H, et al. PUMA regulates intestinal progenitor cell radiosensitivity and gastrointestinal syndrome. Cell Stem Cell 2008; 2: 576-583.
76. Potten CS. Radiation, the ideal cytotoxic agent for studying the cell biology of tissues such as the small intestine. Radiat Res 2004; 161: 123-136.
77. Mustata G, Li M, Zevola N, et al. Development of Small-Molecule PUMA Inhibitors for Mitigating Radiation-Induced Cell Death. Curr Top Med Chem 2010.
78. Smits C, Czabotar PE, Hinds MG, Day CL. Structural plasticity underpins promiscuous binding of the prosurvival protein A1. Structure 2008; 16: 818-829.
79. Day CL, Smits C, Fan FC, Lee EF, Fairlie WD, Hinds MG. Structure of the BH3 domains from the p53-inducible BH3-only proteins Noxa and Puma in complex with Mcl-1. J Mol Biol 2008; 380: 958-971.
80. Irwin JJ, Shoichet BK. ZINC--a free database of commercially available compounds for virtual screening. J Chem Inf Model 2005; 45: 177-182.
81. Tompa P. Unstructural biology coming of age. Curr Opin Struct Biol 2011; 21: 419-425.
82. Markart P, Korfhagen TR, Weaver TE, Akinbi HT. Mouse lysozyme M is important in pulmonary host defense against Klebsiella pneumoniae infection. Am J Respir Crit Care Med 2004; 169: 454-458.
83. Akinbi HT, Epaud R, Bhatt H, Weaver TE. Bacterial killing is enhanced by expression of lysozyme in the lungs of transgenic mice. J Immunol 2000; 165: 5760-5766.
84. Cole AM, Thapa DR, Gabayan V, Liao HI, Liu L, Ganz T. Decreased clearance of Pseudomonas aeruginosa from airways of mice deficient in lysozyme M. J Leukoc Biol 2005; 78: 1081-1085.
85. Monchois V, Abergel C, Sturgis J, Jeudy S, Claverie JM. Escherichia coli ykfE ORFan gene encodes a potent inhibitor of Ctype lysozyme. Journal of Biological Chemistry 2001; 276: 18437-18441.
86. Callewaert L, Aertsen A, Deckers D, et al. A new family of lysozyme inhibitors contributing to lysozyme tolerance in gramnegative bacteria. PLoS Pathog 2008; 4: e1000019.
87. Voet A, Callewaert L, Ulens T, et al. Structure based discovery of small molecule suppressors targeting bacterial lysozyme inhibitors. Biochemical and biophysical research communications 2011; 405: 527-532.
88. Yum S, Kim MJ, Xu Y, et al. Structural basis for the recognition of lysozyme by MliC, a periplasmic lysozyme inhibitor in Gramnegative bacteria. Biochem Biophys Res Commun 2009; 378: 244-248.
89. Callewaert L, Vanderkelen L, Deckers D, Aertsen A, Robben J, Michiels CW. Detection of a lysozyme inhibitor in Proteus mirabilis by a new reverse zymogram method. Appl Environ Microbiol 2008; 74: 4978-4981.
90. Sarafianos SG, Marchand B, Das K, et al. Structure and function of HIV-1 reverse transcriptase: molecular mechanisms of polymerization and inhibition. J Mol Biol 2009; 385: 693-713.
91. Mulky A, Sarafianos SG, Jia Y, Arnold E, Kappes JC. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions. J Mol Biol 2005; 349: 673-684.
92. Wapling J, Moore KL, Sonza S, Mak J, Tachedjian G. Mutations that abrogate human immunodeficiency virus type 1 reverse transcriptase dimerization affect maturation of the reverse transcriptase heterodimer. J Virol 2005; 79: 10247-10257.
93. Grohmann D, Corradi V, Elbasyouny M, et al. Small molecule inhibitors targeting HIV-1 reverse transcriptase dimerization. Chembiochem 2008; 9: 916-922.
94. Tintori C, Corradi V, Magnani M, Manetti F, Botta M. Targets looking for drugs: a multistep computational protocol for the development of structure-based pharmacophores and their applications for hit discovery. J Chem Inf Model 2008; 48: 2166-2179.
95. Reynes C, Host H, Camproux AC, et al. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol; 6: e1000695.
96. Sperandio O, Reynes CH, Camproux AC, Villoutreix BO. Rationalizing the chemical space of protein-protein interaction inhibitors. Drug Discov Today; 15: 220-229.
97. Neugebauer A, Hartmann RW, Klein CD. Prediction of proteinprotein interaction inhibitors by chemoinformatics and machine learning methods. J Med Chem 2007; 50: 4665-4668.
98. Zhao Y, Li W, Zeng J, Liu G, Tang Y. Insights into the interactions between HIV-1 integrase and human LEDGF/p75 by molecular dynamics simulation and free energy calculation. Proteins 2008; 72: 635-645.
99. Tintori C, Veljkovic N, Veljkovic V, Botta M. Computational studies of the interaction between the HIV-1 integrase tetramer and the cofactor LEDGF/p75: insights from molecular dynamics simulations and the informational spectrum method. Proteins 2010; 78: 3396-3408.
100. Chemical Computing Group Inc. SSW, Suite #910, Montreal, QC, Canada, H3A 2R7 2011. Molecular Operating Environment (MOE) 2011.10. In: ed.^eds. 2011.